Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05606718
Other study ID # DEFORM trial
Secondary ID
Status Recruiting
Phase Phase 4
First received
Last updated
Start date April 1, 2022
Est. completion date July 31, 2023

Study information

Verified date February 2023
Source Sun Yat-sen University
Contact Xiaodong Zhuang, Dr
Phone +86 02087338190
Email zhuangxd3@mail.sysu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Functional mitral regurgitation (FMR) leads to various adverse outcomes. Cardiac remodeling (CR) and myocardial fibrosis (MF) are closely related to FMR, forming a vicious circle of CR-FMR-MF and resulting in the end-stage heart failure (HF). The optimal therapeutic strategies of FMR require to effectively break the vicious circle of CR-FMR-MF and still remain full of controversy, especially in the appropriate selection of patients suitable for transcatheter treatment. Regardless, adequate guideline-directed medical therapy (GDMT) is always the most important therapy of FMR. Currently GDMT for FMR included β-blockers, renin-angiotensin system (RAS) inhibitors and mineralocorticoid receptor antagonists (MRA). Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, have been proven to be effectively in reducing cardiovascular death and worsening HF in HF patients. However, there is still no evidence support the use of SGLT2i in FMR therapy due to the lack of relevant clinical trial. The DEFORM trial aims to assess the efficacy of dapagliflozin in reducing the extent of mitral regurgitation and myocardial fibrosis in FMR patients. DEFORM trial is a multi-center, prospective, randomized, parallel controlled, investigator-initiated trial enrolling a planned 98 FMR patients. Patients will be randomly assigned in a 1:1 ratio to either dapagliflozin 10mg once daily for 3 months or placebo. The primary outcome is the change in effective regurgitant orifice area (EROA) of mitral regurgitation measured by echocardiography. Secondary end-points include change change in regurgitant volume (RV), left ventricular end-systolic volume (LVESV), left ventricular end-diastolic volume (LVEDV) (echocardiography), change in NT-proBNP levels and occurrence of major adverse cardiac events (MACEs).


Description:

Inclusion criteria: - Patients aged >18 years and <90 years - LVEF<60% and EROA of mitral regurgitation≥0.2cm2 on echocardiography - The structure of mitral valve leaf and chordae tendineae is normal - Patients have received GDMT for FMR including a stable, optimized dose of β-blocker and RAAS inhibitors for at least 2 weeks - No intravenous anti-heart failure drugs used for the past 2 weeks - Written informed consent Exclusion criteria: - Allergic to dapagliflozin, or angioedema - Already taking dapagliflozin or other SGLT2 inhibitors - Presence of primary structural damage to the mitral valve, such as rheumatic heart disease, mitral valve prolapses - Non-dialysis chronic kidney disease (CKD) patients with eGFR <30ml/min/1.73m2 or dialysis patients - Acute myocardial infarction and acute myocarditis occurred within 3 months - Revascularization procedure, CRT, TMVR, surgical valve repair or replacement were performed or planed 3 months before or after enrollment - Combining significant aortic valve diseases (moderate or severe regurgitation or stenosis) - Combining hyperthyroidism while thyroid function has not returned to normal - Pregnant or lactation women


Recruitment information / eligibility

Status Recruiting
Enrollment 98
Est. completion date July 31, 2023
Est. primary completion date June 30, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: - Patients aged >18 years and <90 years - LVEF<60% and EROA of mitral regurgitation=0.2cm2 on echocardiography - The structure of mitral valve leaf and chordae tendineae is normal - Patients have received GDMT for FMR including a stable, optimized dose of ß-blocker and RAAS inhibitors for at least 2 weeks Exclusion Criteria: - Allergic to dapagliflozin, or angioedema - Already taking dapagliflozin or other SGLT2 inhibitors - Presence of primary structural damage to the mitral valve, such as rheumatic heart disease, mitral valve prolapses - Non-dialysis chronic kidney disease (CKD) patients with eGFR <30ml/min/1.73m2 or dialysis patients - Acute myocardial infarction and acute myocarditis occurred within 3 months - Revascularization procedure, CRT, TMVR, surgical valve repair or replacement were performed or planed 3 months before or after enrollment - Combining significant aortic valve diseases (moderate or severe regurgitation or stenosis) - Combining hyperthyroidism while thyroid function has not returned to normal - Pregnant or lactation women

Study Design


Intervention

Drug:
Dapagliflozin
dapagliflozin 10mg once daily for 3 months after randomization
Other:
guideline-directed medical therapy (GDMT)
guideline-directed medical therapy (GDMT)

Locations

Country Name City State
China The First Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong
China The Third Affiliated Hospital of Sun Yat-Sen University Guangzhou Guangdong
China The Third Affiliated Hospital of Sun Yat-sen University Yuedong Hospital Meizhou Guangdong

Sponsors (1)

Lead Sponsor Collaborator
Sun Yat-sen University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary EROA of FMR Change in EROA of mitral regurgitation evaluated by echocardiography from baseline to 12 weeks follow-up 3 months
Secondary cardiac structure Change in RV measured by echocardiography from baseline to 12 weeks follow-up 3 months
Secondary MACE Occurrence of MACE in 12 weeks follow-up 3 months
Secondary cardiac function Change in serum NT-proBNP levels from baseline to 12 weeks follow-up 3 months
See also
  Status Clinical Trial Phase
Completed NCT02520310 - AVJ-514 Japan Trial N/A
Not yet recruiting NCT04396379 - Epicardial Mitral Touch System for Mitral Insufficiency N/A
Not yet recruiting NCT05566340 - Treatment of Moderate FMR During AVR
Completed NCT01899573 - Percutaneous Left Ventricular Reshaping to Reduce Functional Mitral Regurgitation and Improve LV Function N/A
Terminated NCT04529928 - An Initial Evaluation of the Carillon Mitral Contour System for Treatment of Atrial Function Mitral Regurgitation N/A
Recruiting NCT03706833 - Edwards PASCAL CLASP IID/IIF Pivotal Clinical Trial N/A
Completed NCT00800046 - A Study of Percutaneous Repair of Functional Mitral Regurgitation Using the Ancora Heart, Inc. AccuCinch® Ventricular Repair System - The CINCH-2 Study N/A
Active, not recruiting NCT03929913 - NHLBI DIR Transcatheter Mitral Cerclage Annuloplasty Early Feasibility Study N/A
Active, not recruiting NCT05988450 - Safety and Effectiveness Study of SQ-Kyrin TMVr System for Functional Mitral Regurgitation N/A
Recruiting NCT03616678 - VenTouch OUS Feasibility Study N/A
Not yet recruiting NCT04679714 - EXPLORE FMR: Early Feasibility Study of the PLAR Implant and Delivery System to Treat Functional Mitral Regurgitation N/A
Active, not recruiting NCT02701972 - Evaluation of Safety and Efficacy of the BACE™ Device in the Treatment of Functional Mitral Valve Regurgitation [FMR N/A
Enrolling by invitation NCT04776798 - Biomechanical Taping on Low Back Pain With Increased Foot Pronation N/A
Enrolling by invitation NCT05677568 - The CINCH-FMR Post-Market Registry: Percutaneous Repair in Functional Mitral Regurgitation
Recruiting NCT03433274 - Clinical Trial to Evaluate the Safety and Effectiveness of Using the Tendyne Transcatheter Mitral Valve System for the Treatment of Symptomatic Mitral Regurgitation N/A
Completed NCT05865938 - PASCAL vs. MitralClip for Mitral Valve Transchatheter Edge-to-Edge Repair
Terminated NCT03016975 - Edwards Cardioband System ACTIVE Pivotal Clinical Trial (ACTIVE) N/A
Completed NCT02471664 - Mitral Loop Cerclage(MLC) for Reducing Functional Mitral Regurgitation N/A
Active, not recruiting NCT02671799 - Evaluation of the Minimally Invasive VenTouch™ System in the Treatment of Functional Mitral Valve Regurgitation (FMR) N/A
Recruiting NCT03142152 - The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR N/A